These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15886563)

  • 41. Listeria infections associated with infliximab: case reports.
    Kesteman T; Yombi JC; Gigi J; Durez P
    Clin Rheumatol; 2007 Dec; 26(12):2173-2175. PubMed ID: 17579802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Infliximab in the treatment of rheumatoid arthritis].
    Akahoshi T; Watabe H
    Nihon Rinsho; 2002 Dec; 60(12):2378-83. PubMed ID: 12510365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(15):2179-208. PubMed ID: 16225377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Fatal miliary tuberculosis during treatment with infliximab].
    Vonkeman HE; van der Valk PD; Mulder L; van de Laar MA
    Ned Tijdschr Geneeskd; 2002 Jun; 146(25):1196-9. PubMed ID: 12109312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disseminated Mycobacterium haemophilum infection in a 72-year-old patient with rheumatoid arthritis on infliximab.
    Collins CS; Terrell C; Mueller P
    BMJ Case Rep; 2013 Mar; 2013():. PubMed ID: 23505273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of autoantibodies induced by infliximab treatment: two-year follow-up after infliximab discontinuation.
    Novak S; Anić B; Anić F; Cerovac M; Cikeš N
    Acta Dermatovenerol Croat; 2011; 19(3):156-60. PubMed ID: 21933639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of infliximab in a patient with rheumatoid arthritis and chronic hepatitis B.
    Doubrawa E; Ricca RA; Malucelli TO; Pizzol VI; Barros DH; Paiva ES
    Rev Bras Reumatol; 2012 Aug; 52(4):653-5. PubMed ID: 22885430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Golimumab-exacerbated subacute cutaneous lupus erythematosus.
    Wilkerson E; Hazey MA; Bahrami S; Callen JP
    Arch Dermatol; 2012 Oct; 148(10):1186-90. PubMed ID: 23069957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Etanercept-induced systemic lupus erythematosus.
    Swale VJ; Perrett CM; Denton CP; Black CM; Rustin MH
    Clin Exp Dermatol; 2003 Nov; 28(6):604-7. PubMed ID: 14616825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Anti-TNF alpha monoclonal antibodies (infliximab) and tuberculosis: apropos of 3 cases].
    Roth S; Delmont E; Heudier P; Kaphan R; Cua E; Castela J; Verdier JM; Chichmanian RM; Fuzibet JG
    Rev Med Interne; 2002 Mar; 23(3):312-6. PubMed ID: 11928379
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TNF-alpha antagonist induced lupus on three different agents.
    Mudduluru BM; Shah S; Shamah S; Swaminath A
    Postgrad Med; 2017 Mar; 129(2):304-306. PubMed ID: 27748629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug-induced lupus erythematosus in a patient treated with adalumimab.
    Spillane AP; Xia Y; Sniezek PJ
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S114-6. PubMed ID: 17434034
    [No Abstract]   [Full Text] [Related]  

  • 55. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
    Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
    JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
    Bondeson J; Maini RN
    Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis.
    Bodur H; Eser F; Konca S; Arikan S
    Rheumatol Int; 2009 Feb; 29(4):451-4. PubMed ID: 18712523
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lupus erythematosus with leflunomide: induction or reactivation?
    Gensburger D; Kawashima M; Marotte H; Kanitakis J; Miossec P
    Ann Rheum Dis; 2005 Jan; 64(1):153-5. PubMed ID: 15608317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.
    Jarrett SJ; Cunnane G; Conaghan PG; Bingham SJ; Buch MH; Quinn MA; Emery P
    J Rheumatol; 2003 Oct; 30(10):2287-91. PubMed ID: 14528531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulmonary infections in patients with rheumatoid arthritis who have received anti-TNF therapy.
    Amano K
    Intern Med; 2006; 45(17):991-2. PubMed ID: 17015997
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.